1. HABERLER

  2. NEWS

  3. BioNTech Company of German Origin Announces Its Huge Income In The Last 3 Months!
BioNTech Company of German Origin Announces Its Huge Income In The Last 3 Months!

BioNTech Company of German Origin Announces Its Huge Income In The Last 3 Months!

The German-based company BioNTech, one of the development partners of the most widely applied coronavirus vaccine worldwide, announced its magnificent profit in the second quarter of this year. The company's income in the same period of the previous year is not close to this period.

A+A-

BioNTech, a biotechnology company based in Germany, has managed to make its name known to the whole world with the coronavirus vaccine it developed in partnership with Pfizer. The company, whose founders include Uğur Şahin and Özlem Türeci, has achieved great success by using the mRNA method in the vaccine. The company also aims to develop vaccines that will fight cancer in the future.

But BioNTech's biggest livelihood today is, of course, coronavirus vaccines. The vaccine, which is used in many countries around the world, especially in EU countries and the USA, brought a great income to the company. The latest figures revealed this income. The data shared by the company showed the net profit in the second quarter of 2021.

usa-biontech-germany.jpg

BioNTech Company Generated 7 billion 356.9 million Euros in Revenue!

According to the announced data, BioNTech generated a revenue of 7 billion 356.9 million Euros in the second quarter of the year, covering the months of April-June. 2 billion 787.2 million Euros of this income was recorded as profit. Thus, the total profit of the company in the first half of 2021, that is, in the first 6 months, increased to 3 billion 915.3 million Euros. Earnings per share in the second quarter was announced as 11.42 Euros.

BioNTech Company Previous Year Revenue Was Below 100 Million Euros!

BioNTech reported a loss of 141.7 million Euros in the first half of last year (January – June 2020). Again in the first half of last year, the company had a revenue of 69.4 million Euros. But with the acceleration of vaccination all over the world, BioNTech has also accelerated. The company signed 2.2 billion doses of vaccine supply contracts this year, generating a total revenue of $15.9 billion from these contracts.

HABERE YORUM KAT

WARNING: Do not forget to comment so that your voices can be heard. We report the comments that attract attention to make your voice heard. Comments that contain swearing, insults, offensive sentences or allusions, attacks on beliefs, are not written with spelling rules, will not be approved.